ArticleNature medicine2020
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
Open access · bronzeAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 363 papers.
0numbers the graph read from it
0cells of the map it votes in
363citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
363 citing papers in PubMed, 537 citations in OpenAlex.
- Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.The Journal of infectious diseases · 2023Trial
- AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.The New England journal of medicine · 2022Trial
- JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space.Nature communications · 2026Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Engineering Viral Surface Antigens to Improve Display on Virus-like Particle (VLP) Vaccine Prototypes.Biotech (Basel (Switzerland)) · 2026Article
- Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.Nature microbiology · 2026Article
- Mining antibody functionality via AI-guided structural landscape profiling.Nature communications · 2026Article
- Advanced fluorescence biosensor utilizing nitrogen/oxygen-doped carbon quantum dots in a modified carboxy cellulose matrix for quantitative detection of SARS-CoV-2 spike protein.Discover nano · 2026Article
- The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response.bioRxiv : the preprint server for biology · 2026Article
- A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode.PLoS pathogens · 2026Article
- Population-level genomic analysis of immunoglobulin loci variation in rhesus macaques reveals extensive germline diversity.Immunity · 2026Article
- Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Optoelectronic Tweezers for Single-Cell Research: Principles, Applications, and Prospects.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- Article
- Clonal interference and changing selective pressures shape the escape of SARS-CoV-2 from hundreds of antibodies.Virus evolution · 2026Article
- Enhancing large particle recovery in high-throughput functional cell sorting through ΔBOP optimization.Scientific reports · 2025Article
- A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active site.The Journal of clinical investigation · 2025Article
- A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses.NPJ vaccines · 2025Article
- Identification of antigen-specific functional CD8iScience · 2025Article
303 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
31 authors at 7 institutions in 2 countries.
Seth J Zost *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6712-5076
Pavlo Gilchuk *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rita E ChenDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Joseph X ReidyVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Andrew TrivetteVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rachel S NargiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Rachel E SuttonVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Naveenchandra SuryadevaraVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Elaine C ChenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-7883-8039
Elad BinshteinVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2745-104X
Swathi ShrihariDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8188-6936
Mario OstrowskiDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Helen Y ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Jonathan E DidierBerkeley Lights, Inc., Emeryville, CA, USA.
Keith W MacRenarisBerkeley Lights, Inc., Emeryville, CA, USA.
Taylor JonesVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Samuel DayVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Luke MyersVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1132-2550
F Eun-Hyung LeeDepartment of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6133-5942
Doan C NguyenDepartment of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-5389-6731
Ignacio SanzDepartment of Medicine, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4182-587X
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Paul W RothlaufProgram in Virology, Harvard Medical School, Boston, MA, USA.
Louis-Marie BloyetDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Sean P J WhelanProgram in Virology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1564-8590
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-9380-6569
Michael S DiamondDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Robert H CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. robert.carnahan@vumc.org.ORCID http://orcid.org/0000-0001-5230-1532
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. james.crowe@vumc.org.ORCID http://orcid.org/0000-0002-0049-1079
Vanderbilt University Medical Center · USWashington University in St. Louis · USEmory University · USHarvard University · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAUniversity of Washington · US
Funding
Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2014 to 2026
$76.6MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MCOVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7MB-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MMolecular Mechanisms of Human Long-lived Plasma Cell Generation in the Bone Marrow and SpleenU01AI141993 · NIAID · EMORY UNIVERSITY · PI Frances Eun-Hyung Lee · 2019 to 2026
$5.7MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MChildhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2MIllumina Genome Analyzer IIS10RR028106 · NCRR · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L. · 2011 to 2011
$515kNCATS NIH HHS UL1 TR000445NCRR NIH HHS S10 RR028106NCRR NIH HHS UL1 RR024975NIAID NIH HHS 75N93019C00062NIAID NIH HHS 75N93019C00074NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007151NIAID NIH HHS T32 AI095202NIAID NIH HHS U01 AI141993NIAID NIH HHS U19 AI110483
Abstract
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingBetacoronavirusCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.